FSGS Archives - Renal Disease Research Institute

SPARX: Safety and efficacy of sparsentan for patients post kidney transplantation with IgAN or FSGS

Protocol Name: SPARX: Safety and efficacy of sparsentan for patients post kidney transplantation with IgAN or FSGS Protocol #: TVTX-RE021-426 Indication: Cardiovascular Event Risk Reduction GFR: ≥25 Principal Investigator: Bernard Fischbach, MD, CCRP Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204 DETAILS >

A study to evaluate the efficacy and safety of frexalimab, brivekimig, and rilzabrutinib in patients with primary FSGS or minimal change disease

authenticweb

Protocol Name: A study to evaluate the efficacy and safety of frexalimab, brivekimig, and rilzabrutinib in patients with primary FSGS or minimal change disease Protocol #: ACT18064 Indication: Fabry Disease GFR: ≥ 45 Principal Investigator: Ankit N. Mehta, MD, FASN Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204 DETAILS >

A study to evaluate the efficacy and safety of frexalimab, brivekimig, and rilzabrutinib in patients with primary FSGS or minimal change disease Read More »